In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- USDH’s AI-Driven Colonoscopy Innovation and Market Expansion: A Disruptive Force in U.S. Preventive Medicine (AInvest)
- Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition (MedCity News)
- How to protect physician autonomy as GI consolidates (Becker’s GI & Endoscopy)
- GutGPT: A multidimensional knowledge-enhanced large language model for gastrointestinal medicine (ScienceDirect)
- 288 new CPT codes cover digital health, AI and more (AMA)
- The Prognostic Power of ctDNA Testing in Patients With Colorectal Cancer (Medscape)
- AI Is Becoming Private Equity’s New Playbook (Forbes)
- Rising colorectal cancer rates and ASCs: 5 things to know (Bevker’s GI & Endoscopy)
